Amy Baxter from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation		What RFK Jr.’s influence could mean for pharma - 9 days ago A diabetes drug, twice rejected, stumbles again — but its developer persists - 11 days ago Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s - 14 days ago 2024 PharmaVoice 100s: Clinical Trial Pros - 18 days ago Backlash builds against Novo’s Catalent takeover - 19 days ago 2024 PharmaVoice 100s: Tech and AI Wizards - 21 days ago Where Big Pharma’s campaign cash is flowing in this election - 21 days ago FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage - 28 days ago 2024 PharmaVoice 100s: Cardiometabolic All-Stars - about 1 month ago As election day nears, Trump and Harris veer in different directions on pharma - about 1 month ago How Roche plans to fill a projected $8B sales gap - about 2 months ago 3 FDA approval dates to watch in the year’s final push - 2 months ago Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies - 2 months ago FDA adcomm reform talks heat up - 3 months ago Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision - 3 months ago BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings - 3 months ago The drugs hit hardest by Medicare price negotiations - 3 months ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 3 months ago A potential MS ‘game changer’ could bring more safety to the table — even against viruses - 3 months ago M&A is ready to explode, and that’s good news for pharma layoffs - 3 months ago Pharma execs react to final drug price negotiations with Medicare - 3 months ago Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 3 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 3 months ago Read to lead: 6 books pharma execs swear by - 4 months ago 3 Big Pharma cancer drugs facing inflation penalties - 4 months ago Sage’s recent trial failure adds pressure to its two-drug Biogen collab - 4 months ago Where Kamala Harris stands on three key pharma issues - 4 months ago To overcome barriers, cell and gene therapies need outside support - 4 months ago Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 4 months ago Is a better CAR-T cell therapy option on the horizon? - 4 months ago BMS’ long-standing leukemia blockbuster stares down its first generic - 4 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 4 months ago The IRA will lower U.S. drug spending, CMS finds — but not for awhile - 5 months ago Will the real Ozempic please stand up? Lilly, Novo face uphill counterfeit battle - 5 months ago Ahead of its upcoming decision date, a competitor takes aim at KarXT - 5 months ago After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners - 5 months ago The hunt for the brain’s biomarkers - 5 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 5 months ago FDA’s platform designation aims to ease R&D pain points - 5 months ago Behind Big Pharma’s layoffs — is there an end in sight? - 5 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 6 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 6 months ago As AI proliferates in pharma, regulators look to catch up in clinical trials - 7 months ago 4 offbeat biotechs making a splash in the life sciences - 7 months ago How a biotech exec is leveraging Big Pharma lessons to advance tRNA - 7 months ago What’s old is new: The revival of a one-time radiotherapy cancer treatment - 7 months ago Cutting pills. Rationing insulin. How Americans struggle to pay for drugs. - 7 months ago Next-gen menopause treatments have blockbuster potential. Can women, doctors and payers be convinced? - 7 months ago Women want to participate in clinical trials. Lack of flexibility is still a problem. - 7 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - 8 months ago